Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

2000455 citationsJournal Article

Authors

Justin S. Waters · Institute of Cancer Research

Andrew Webb · Institute of Cancer Research

David Cunningham · Institute of Cancer Research

Paul A. Clarke · Institute of Cancer Research

Florence I. Raynaud · Institute of Cancer Research

Francesca Di Stefano · Institute of Cancer Research

Finbarr E. Cotter

Abstract

Bcl-2 antisense therapy is feasible and shows potential for antitumor activity in NHL. Downregulation of Bcl-2 protein suggests a specific antisense mechanism.

Topics & Keywords

Lymphoma Diagnosis and Treatment RNA Interference and Gene Delivery Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 18, Issue 9, pp. 1812-1823

DOI: 10.1200/jco.2000.18.9.1812

Field-Weighted Citation Impact: 41.37